Welcome to our dedicated page for Horizon Therapeutics Pub L news (Ticker: HZNP), a resource for investors and traders seeking the latest updates and insights on Horizon Therapeutics Pub L stock.
Horizon Therapeutics plc (NASDAQ: HZNP) is a global biotechnology leader focused on developing therapies for rare, autoimmune, and severe inflammatory diseases. This dedicated news hub provides investors and healthcare professionals with timely updates on regulatory milestones, research breakthroughs, and strategic corporate initiatives shaping the company's trajectory.
Access authoritative information on Horizon's innovative treatments like TEPEZZA® and KRYSTEXXA®, along with analysis of key developments including partnership announcements and regulatory filings. Our curated news collection serves as your primary resource for understanding Horizon's position in the biopharmaceutical landscape and its commitment to addressing unmet medical needs.
Key updates cover clinical trial progress, FDA communications, financial results, and major corporate events such as Horizon's pending acquisition by Amgen following FTC clearance. All content is sourced from official releases and verified channels to ensure accuracy and compliance with financial reporting standards.
Bookmark this page for streamlined access to Horizon Therapeutics' evolving story. For additional context on the company's mission and pipeline, visit their official website at HorizonTherapeutics.com.
Horizon Therapeutics plc (Nasdaq: HZNP) presented new findings from its clinical trials at ENDO 2022, focusing on the safety profile of TEPEZZA for treating Thyroid Eye Disease (TED). The analysis reported a 10% incidence of hyperglycemia in patients treated with TEPEZZA, primarily affecting those with pre-existing diabetes. Importantly, all hyperglycemic events were manageable, with no treatment disruptions. A secondary analysis also confirmed TEPEZZA's efficacy in mildly hypothyroid patients, yielding outcomes consistent with broader trial results. These findings reinforce TEPEZZA's role in managing TED.
Horizon Therapeutics has been recognized as a Top 75 Company for Executive Women by Seramount, highlighting its commitment to diversity and female advancement in leadership roles. The company's initiatives include equal pay commitments, extensive maternity leave, and on-site childcare benefits. CEO Tim Walbert emphasized the organization's focus on creating a culture of growth and support for women. This accolade reflects Horizon's strategic approach to fostering an inclusive workplace aimed at attracting top talent.
Horizon Therapeutics plc (Nasdaq: HZNP) will participate in the Goldman Sachs 43rd Annual Global Health Care Conference on June 14, 2022, at 11 a.m. ET. The event will be available via live webcast on Horizon's website, with a replay accessible for one year post-event. Horizon focuses on developing therapies for rare, autoimmune, and severe inflammatory diseases, emphasizing scientific innovation and patient impact. For further details, visit their website.
Horizon Therapeutics (HZNP) will present new data on Thyroid Eye Disease (TED) at the Endocrine Society’s Annual Conference (ENDO 2022) from June 11-14 in Atlanta. Key presentations include the efficacy of Teprotumumab and its impact on blood glucose in TED patients. Gail Devers, a three-time Olympic gold medalist living with Graves' disease and TED, will discuss her journey and advocate for early symptom recognition. Horizon will also host a product theater on TED treatment advancements. These efforts emphasize the company's commitment to addressing unmet needs in rare autoimmune diseases.
Horizon Therapeutics (HZNP) reported promising results from the MIRROR clinical trial for KRYSTEXXA (pegloticase) combined with methotrexate. Data showed a greater than 32% increase in patient response rates, with 71% of patients achieving a sustained urate-lowering response. Infusion reactions dropped from 31% to 4%. The FDA has granted priority review for the supplemental biologic license application with a decision expected by July 7, 2022. Presentations will be made at the EULAR 2022 congress from June 1–4 in Copenhagen.
Horizon Therapeutics (HZNP) announced pivotal Phase 3 trial data for UPLIZNA presented at the CMSC Annual Meeting (June 1-4). The results indicate UPLIZNA's effectiveness in reducing the risk of attacks and disability in NMOSD patients, irrespective of genetic variations like the FCGR3A polymorphism that typically hinder treatment efficacy. 142 participants were genotyped, with no significant differences in disease attacks noted based on genotype. These findings underscore UPLIZNA's unique design and potential for personalized treatment approaches.
Horizon Therapeutics plc (NASDAQ: HZNP) announced significant data presentations at the EULAR 2022 European Congress of Rheumatology, focusing on KRYSTEXXA® (pegloticase injection) for uncontrolled gout. Key findings from the MIRROR trial showcased improved response rates and safety profiles. Notable presentations include the effectiveness of KRYSTEXXA combined with methotrexate and the psychosocial impacts of gout. Horizon emphasizes the congress as crucial for sharing insights that may influence treatment standards for gout patients.
Horizon Therapeutics (NASDAQ: HZNP) announced the enrollment of the first patient in a Phase 2 trial for daxdilimab (HZN-7734), a monoclonal antibody targeting ILT7. This trial aims to address moderately severe alopecia areata, a prevalent autoimmune disorder affecting over 600,000 individuals in the U.S. The study will include approximately 30 participants, evaluating hair loss severity with a primary endpoint of percent change in Severity of Alopecia Tool (SALT) scores at Week 24. The unmet medical need for effective treatments for alopecia areata underscores the importance of this trial.
